Next Article in Journal
Retinal Macrophage-Like Cells as a Biomarker of Inflammation in Retinal Vein Occlusions
Next Article in Special Issue
Transvenous Pulmonary Chemoembolization and Optional Microwave Ablation for Colorectal Lung Metastases
Previous Article in Journal
Ultrasonic Diagnosis and Management of Posthemorrhagic Ventricular Dilatation in Premature Infants: A Narrative Review
Previous Article in Special Issue
Internal Iliac Artery Embolization within EVAR Procedure: Safety, Feasibility, and Outcome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 24
10.3390/jcm11247469
Review Report
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Improved Survival after Transarterial Radioembolisation for Hepatocellular Carcinoma Gives the Procedure Added Value

J. Clin. Med. 2022, 11(24), 7469; https://doi.org/10.3390/jcm11247469
by Cristina Mosconi 1, Alberta Cappelli 1, Cinzia Pettinato 2, Maria Adriana Cocozza 1,*, Giulio Vara 1, Eleonora Terzi 3, Maria Cristina Morelli 4, Elisa Lodi Rizzini 5, Matteo Renzulli 1, Francesco Modestino 1, Matteo Serenari 6, Rachele Bonfiglioli 7, Letizia Calderoni 7, Elena Tabacchi 7, Matteo Cescon 6, Alessio Giuseppe Morganti 5, Franco Trevisani 8, Fabio Piscaglia 3, Stefano Fanti 7, Lidia Strigari 9, Alessandro Cucchetti 10,11,† and Rita Golfieri 1,12,†add Show full author list remove Hide full author list
Reviewer 1: Anonymous
Reviewer 2:
Katsunori Yoshida
J. Clin. Med. 2022, 11(24), 7469; https://doi.org/10.3390/jcm11247469
Submission received: 20 October 2022 / Revised: 9 December 2022 / Accepted: 13 December 2022 / Published: 16 December 2022
(This article belongs to the Special Issue Embolization Techniques: State of the Art and Future Perspectives)

Round 1

Reviewer 1 Report

Thanks for the opportunity to review this retrospective study investigating possibilities to improve TARE in HCC.

The study is well written and data presentation is very good.

As most studies in advanced HCC, data derrives from the time of Sorafenib as the only approved systemic treatment. Yet, we are heading towards a new era of immunotherapy. Although the study data is older, recent results of studies such as IMBrave150 must be mentioned as it must at least be assumed that subsequent immunotherapy after TARE will further prolong survival compared to Sorafenib.

This is fortunately the only aspect missing in this study. Congratulations!

Author Response

"Please see the attachment."

Author Response File: Author Response.docx

Reviewer 2 Report

 

Final comments:

This paper shows that transarterial radioembolisation (TARE) is one of the good strategies for advanced HCC patients.Their data looks reasonable and conclusions encourage for patients who could not stop HCC growth by other treatment. 

One thing, I would like to know is that are there any technical differences between TACE and TARE. Please discuss this point at discussion.

 

 

 

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop